Role of Dosf, Schedule and Route of Administration of 5-Formyltetra-Hydrofolate: Preclinical and Clinical Investigations

  • Y. M. Rustum
  • L. Liu
  • Z. Zhang
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 131)


During the last 30 years, 5-fluorouracil (FUra)* has been the drug of choice for treatment of patients with adenocarcinoma of the colon. This agent is also active against breast carcinoma and has significant activity in carcinoma of the head and neck. In all cases, but especially in colon carcinoma, the response rate is low and the duration of response is relatively short, on the order of 6 to 9 months.


Antitumor Activity Pyrimidine Nucleoside Concentration Time Curve Tinuous Infusion Uridine Monophosphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D.S. Martin, R.L. Stolfi, R.C. Sawyer, and C.W. Young. The application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy. Cancer Treat. Rep., 69: 421–423 (1985).Google Scholar
  2. 2.
    D.S. Martin, R.L. Stolfi, and S. Spiegelman, Striking augmentation of the in vivo anticancer activity of 5-fluorouracil by combination with pyrimidine nucleosides: an RNA effect, Proc. Am. Assoc. Cancer Res. 19: 221 (1978).Google Scholar
  3. 3.
    R. Nayak, D.S. Martin, R.L. Stolfi, J. Furth, and S. Spiegelman. Pyrimidine nucleosides enhance the anticancer activity of 5-fluorouracil and augment its incorporation into nuclear RNA, Proc. Am. Assoc. Cancer Res. 19: 1963 (1978).Google Scholar
  4. 4.
    D.S. Martin, R.L. Stolfi, R.C. Sawyer, R. Nayak, S. Spiegelman, C.W. Young, and T. Woodcock. An overview of thymidine, Cancer 45: 1117–1128 (1980).PubMedCrossRefGoogle Scholar
  5. 5.
    R.I. Glazer and K.D. Hartman. The effect of 5-fluorouracil on the synthesis and methylation of low molelcular weight nuclear RNA in L1210 cells, Mol. Pharmacol., 17: 245–249 (1979).Google Scholar
  6. 6.
    D.W. Kufe, P.P. Major, E.M. Egan, and E. Loh. 5-Fluoro-2’-Deoxyuridine incorporation into L1210 DNA. J. Biol. Chem., 256: 8885–8888 (1981).PubMedGoogle Scholar
  7. 7.
    P.V. Danenberg, C. Heidelberger, M. Mulkins, and A.R. Peterson. the incorporation of 5-fluoro-2’-deoxyuridine into dNA of mammalian tumor cells. Biochem. Biophys. Res. Commun. 102: 654–558 (1981).PubMedCrossRefGoogle Scholar
  8. 8.
    J.D. Schuetz, H.J. Wallace, and R.B. Diasio. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity, Cancer Res. 44: 1358–1363 (1984).PubMedGoogle Scholar
  9. 9.
    D.V. Santi, C.S. McHenry, and H. Sommer. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry, 13: 471–480 (1974).PubMedCrossRefGoogle Scholar
  10. 10.
    P.V. Danenberg. The role of reduced folates in the enhanced binding of FdUMP to dTMP synthetase. In: The Current Status of 5-Fluorouracil Leucovorin Calcium Combination, Bruckner, H.W. and Rustum, Y.M. eds., p. 5–11, Park Row Publishers, New York (1984).Google Scholar
  11. 11.
    J.A. Houghton and P.J. Houghton. On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xeno-grafts maintained in immune-deprived mice, Cancer, 45: 1159–1167 (1980).PubMedCrossRefGoogle Scholar
  12. 12.
    J.A. Houghton, S.J. Maroda, J.O. Philips, and P.J. Houghton. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res., 41: 144–149 (1981).PubMedGoogle Scholar
  13. 13.
    J.A. Houghton, C. Schmidt and P.J. Houghton. The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthetase covalent complex in human colon xenografts. Eur. J. Cancer Clin. Oncol., 18: 347–354 (1982).PubMedCrossRefGoogle Scholar
  14. 14.
    J.A. Houghton and P.J. Houghton. Basis for the interaction of 5-Fluorouracil and leucovorin in colon adenocarcinoma. In: The Current Status of 5-Fluorouracil-Leucovorin Calcium Combination, Bruckner, H.W. and Rustum, Y.M., eds., p. 23–32, Park Row Publishers, New York (1984).Google Scholar
  15. 15.
    R.M. Evans, J.D. Laskin and M.T. Hakala. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Pes., 41: 3288–3295 (1981).Google Scholar
  16. 16.
    M-B. Yin, S.F. Zakrzewski and M.T. Hakala. Relationship cf cellular folate cofactor pools to activity of 5-fluorouracil. Mol. Pharmacol. 23: 190–197 (1983).PubMedGoogle Scholar
  17. 17.
    F. Trave, Y.M. Rustum, N. Petrelli, L. Herrera, A. Mittelman, C. Frank and P.J. Creaven, Plasmic tumor tissue pharmacology of high dose intravenous 5-formyltetrahydrofolate in combination with 5-fluorouracil in patients with advanced colorectal carcinoma, J. Clinical Oncology 6: 1184 (1988).Google Scholar
  18. 18.
    R.J. Moran, C.P. Spears and C. Heidelberger, Biochemical determinants of tumor sensitivity to the fluorouracil: Ultrasensitive method for the determination of 5-fluorodeoxyuridine monophosphate and thymidylate synthase, Proc. Natl. Acad. Sci. USA 76: 1456 (1969).CrossRefGoogle Scholar
  19. 19.
    L. Danhauser and Y.M. Rustum, A method for continuous drug infusion in unrestarained rats: Its application in the evaluation of the toxicity of 5-fluorouracil/thymidine combination, J. Lab. Clin. Med. 92: 1047 (1979).Google Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Y. M. Rustum
    • 1
  • L. Liu
    • 1
  • Z. Zhang
    • 1
  1. 1.Grace Cancer Drug Center and Experimental TherapeuticsRoswell Park Memorial InstituteBuffaloUSA

Personalised recommendations